Ovarian Cancer Clinical Trials in Richmond, Virginia

3 studies are recruiting for ovarian cancer in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

   Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Virginia Commonwealth University Medical Center /ID# 277932, Richmond, Virginia

   Locations

   86 in total

   Run by

   AbbVie

   See if you can join NCT07059845 on ClinicalTrials.gov

2. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

   The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Virginia Commonwealth University/ Massey Cancer Center, Richmond, Virginia

   Locations

   25 in total

   Run by

   Mayo Clinic

   See if you can join NCT05051722 on ClinicalTrials.gov

3. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Virginia, Richmond, Virginia

   Locations

   9 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04606914 on ClinicalTrials.gov